Last reviewed · How we verify
NCT06936527: XS-03-II201
XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation
Phase 1, PHASE2 trial testing Drug: XS-03, Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI in Colorectal Cancer in 102 participants. Enrolling by invitation.
30 April 2028
Quick facts
| Lead sponsor | NovaOnco Therapeutics Co., Ltd. |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 102 |
| Start date | 23 May 2025 |
| Primary completion | 30 April 2028 |
| Estimated completion | 30 July 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- Drug: XS-03, Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI — full drug profile →
- Drug: XS-03 — full drug profile →
- Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI — full drug profile →
Conditions studied
- Colorectal Cancer — all drugs for Colorectal Cancer →
- Metastatic Colorectal Cancer With RAS Mutation — all drugs for Metastatic Colorectal Cancer With RAS Mutation →
Sponsor
NovaOnco Therapeutics Co., Ltd. — full company profile →
Who can join
Adults 18 to 70, any sex, with Colorectal Cancer or Metastatic Colorectal Cancer With RAS Mutation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
XS-03 in combination with FOLFOX or FOLFIRI and Bevacizumab for treatment of metastatic colorectal cancer patients with RAS mutation
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06936527
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colorectal Cancer
Currently open trials in the same condition.
- NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
- NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting
Other NovaOnco Therapeutics Co., Ltd. trials
Trials by the same sponsor.
- NCT06820268 — A Study of XS-04 in Patients with Relapsed or Refractory Hematologic Malignancies · Phase 1 · recruiting
- NCT06531486 — A Study of XS-02 Capsules in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06936527 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by NovaOnco Therapeutics Co., Ltd.
- Last refreshed: 3 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06936527.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing